Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Akers Biosciences has appointed Trinity Biotech as a distributor of its unique PIFA Heparin/Platelet Factor-4 rapid assay in the US and German markets.
Subscribe to our email newsletter
The test detects the presence of Heparin/PF-4 antibody, which is associated with patients at risk for heparin-induced thrombocytopenia (HIT), and is rapidly becoming a standard of care in hematology and cardiology. The ABI assay is said to be the first rapid test in the world for HIT and the only test available on the market that can provide real-time information that can be useful in formulating a clinical diagnosis.
The HPF4 test is currently being sold into the US clinical laboratory market under the name ‘PIFA Heparin/PF-4 Rapid Assay’. The test is being promoted as a replacement for current laboratory tests used in the detection of a heparin ‘allergy’ or other serious thrombolytic reaction resulting from heparin treatment.
In selling this product, Trinity Biotech will target coagulation and haematology laboratories and clinical settings, such as emergency room, surgical and dialysis units in the hospital markets where Trinity already sells its existing products.
Thomas Nicolette, CEO of Akers Biosciences, said: “We are pleased to be widening the distribution through Trinity Biotech of our HPF4 product, which we believe must become a standard of care in anticoagulant therapy across the globe.”